MARINUS PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.2 USD | 0.00% |
|
-6.25% | -88.96% |
| 07-01 | Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 3000E Growth Index | CI |
| 07-01 | Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 2000 Growth Index | CI |
Presenter SpeechRumen Vasilev;J.P. Morgan Securities LLC;Investment Banking Associate (Analyst...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Companyâs new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The Company is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). It is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
1.2
USD
Average target price
6.667
USD
Spread / Average Target
+455.56%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -88.96% | 65.92M | |
| +57.48% | 823B | |
| -7.18% | 353B | |
| +15.37% | 320B | |
| +7.45% | 295B | |
| +13.62% | 239B | |
| +14.55% | 220B | |
| -0.33% | 219B | |
| +8.14% | 167B | |
| -2.99% | 159B |
- Stock Market
- Equities
- MRNS Stock
- News Marinus Pharmaceuticals, Inc.
- Transcript : Marinus Pharmaceuticals, Inc. Presents at 38th Annual J.P Morgan Healthcare Conference, Jan-16-2020 11
